Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Richard R. Furman | Researchclopedia

Back to researchers

Richard R. Furman

Cornell University ORCID

499

Works

32,979

Citations

75

h-index

244

i10-index

Research Topics

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Immunodeficiency and Autoimmune Disorders

Affiliations

University of Vermont2012–2012

San Antonio College2013–2013

University of North Carolina at Chapel Hill2013–2013

Fox Chase Cancer Center2006–2013

Memorial Sloan Kettering Cancer Center2014–2014

Top Works

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd,Richard R. Furman,et al.

20132,236 citations

Chronic Myeloid Leukemia Treatments

Monoclonal and Polyclonal Antibodies Research

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman,Jeff P. Sharman,et al.

20141,676 citations

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd,Jennifer R. Brown,et al.

20141,603 citations

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre,Christoph Licht,et al.

20131,540 citations

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Jennifer A. Woyach,Richard R. Furman,et al.

20141,240 citations

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani,Joseph J. Buggy,et al.

20121,110 citations

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd,Bonnie K. Harrington,et al.

2015881 citations

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Kenneth R. Carson,Andrew M. Evens,et al.

2009868 citations

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky,Kyle A. Beckwith,et al.

2013787 citations